BioMérieux: confirms targets for fiscal 2023
In Clinical Applications, which account for around 84% of the Group's total cumulative sales, sales in Q3 2023 were up 7% on Q3 2022
Sales in Industrial Applications, which account for around 16% of the Group's sales, were up by more than 6%, reaching almost 138 million euros at the end of Q3 2023.
The Group confirms its 2023 targets. It expects organic sales growth of between +4% and +6% and a contribution margin of between €600 million and €630 million.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction